Author:

Keywords:

Science & Technology, Life Sciences & Biomedicine, Medicine, Research & Experimental, Pharmacology & Pharmacy, Research & Experimental Medicine, aspiration/motility study, in vivo dissolution, local drug concentration in the GI tract, ibuprofen, immediate release, bioequivalence, bioavailability, oral absorption, motility, manometry, IN-VIVO DISSOLUTION, MIGRATING MOTOR COMPLEX, ORAL ABSORPTION, PANCREATIC-SECRETION, WEAK ACID, DRUG, PHARMACOKINETICS, BIOEQUIVALENCE, SIMULATOR, MOTILITY, Administration, Oral, Adult, Area Under Curve, Biological Availability, Biological Variation, Individual, Biological Variation, Population, Datasets as Topic, Drug Liberation, Fasting, Female, Gastrointestinal Absorption, Gastrointestinal Tract, Healthy Volunteers, Humans, Hydrogen-Ion Concentration, Ibuprofen, Male, Middle Aged, Models, Biological, Solubility, Tablets, Young Adult, 0303 Macromolecular and Materials Chemistry, 1115 Pharmacology and Pharmaceutical Sciences, 3214 Pharmacology and pharmaceutical sciences

Abstract:

The goal of this project was to explore and to statistically evaluate the responsible gastrointestinal (GI) factors that are significant factors in explaining the systemic exposure of ibuprofen, between and within human subjects. In a previous study, we determined the solution and total concentrations of ibuprofen as a function of time in aspirated GI fluids, after oral administration of an 800 mg IR tablet (reference standard) of ibuprofen to 20 healthy volunteers in fasted state conditions. In addition, we determined luminal pH and motility pressure recordings that were simultaneously monitored along the GI tract. Blood samples were taken to determine ibuprofen plasma levels. In this work, an in-depth statistical and pharmacokinetic analysis was performed to explain which underlying GI variables are determining the systemic concentrations of ibuprofen between (inter-) and within (intra-) subjects. In addition, the obtained plasma profiles were deconvoluted to link the fraction absorbed with the fraction dissolved. Multiple linear regressions were performed to explain and quantitatively express the impact of underlying GI physiology on systemic exposure of the drug (in terms of plasma Cmax/AUC and plasma Tmax). The exploratory analysis of the correlation between plasma Cmax/AUC and the time to the first phase III contractions postdose (TMMC-III) explains ∼40% of the variability in plasma Cmax for all fasted state subjects. We have experimentally shown that the in vivo intestinal dissolution of ibuprofen is dependent upon physiological variables like, in this case, pH and postdose phase III contractions. For the first time, this work presents a thorough statistical analysis explaining how the GI behavior of an ionized drug can explain the systemic exposure of the drug based on the individual profiles of participating subjects. This creates a scientifically based and rational framework that emphasizes the importance of including pH and motility in a predictive in vivo dissolution methodology to forecast the in vivo performance of a drug product. Moreover, as no extensive first-pass metabolism is considered for ibuprofen, this study demonstrates how intraluminal drug behavior is reflecting the systemic exposure of a drug.